John Leonard, PhD, on RNA-Targeting Gene Therapy for ALS, DMD
The chief scientific officer of LocanaBio discussed preclinical research presented at ASGCT 2023.
“I think this is the first in vivo demonstration of dual targeting in the context of a disease where we know that the pathology is driven from both sense and antisense transcripts. And we do this without knocking down the wild type expression of C9orf, which people are concerned about for haplo-insufficiency as a potential contributor to [ALS]. So, that work I think looks really good.We're now focused on delivery of those constructs. So,what's the best capsule? And what's the best route of administration? But from a targeting perspective, and from a safety perspective, the data looks quite compelling.”
Cas13d-MT, LocanaBio’s preclinical CRISPR/cas9-based, adeno-associated virus vector (AAV) gene therapy, decreased biomarkers associated with C9orf72 amyotrophic lateral sclerosis (ALS). New in vivo and in vitro research showed that the therapy led to a significant reduction of both sense and antisense hexanucleotide repeat expansioncontaining RNAs, a 50-60% decrease in poly-GP dipeptide repeat proteins, and maintenance of total C9orf72 mRNA levels. The transgene showed sustained expression with no signs of toxicity at 6 to 8 weeks after treatment.
These data were presented at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting, held May 16-20, in Los Angeles, California. CGTLive spoke with LocanaBio’s chief scientific officer, John Leonard, PhD, to learn more about Cas13d-MT and its potential advantages in treating ALS. He discussed progress and future milestones for the Cas113d-MT program, which is currently not prioritized by the company, and the AAV9 exon 51 skipping program for Duchenne muscular dystrophy (DMD), which is the company’s lead candidate.
Click here to read more coverage of the ASGCT 2023 meeting.
